Generation of Toxoplasma gondii GRA1 protein and DNA vaccine loaded chitosan particles: Preparation, characterization, and preliminary in vivo studies

International Journal of Pharmaceutics

Volumn 266, Issue 1-2, 2003, Pages 17-27

  Bivas Benita, Maytal ^a   Laloup, Marleen ^b   Versteyhe, Soetkin ^a   Dewit, Joelle ^c   De Braekeleer, Jos ^c   Jongert, Erik ^c   Borchard, Gerrit ^a  

^a LEIDEN UNIVERSITY   (Netherlands)

^b Natl Inst Criminalistics/Criminol   (Belgium)

^c PASTEUR INSTITUTE OF BRUSSELS   (Belgium)

Author keywords

Chitosan; DNA vaccine; GRA 1; Mucosal vaccination; Toxoplasmosis

Indexed keywords

CHITIN; CHITOSAN; DEOXYRIBONUCLEASE I; DNA VACCINE; DRUG CARRIER; DRUG DERIVATIVE; GRA1 ANTIGEN; GRA1 PROTEIN; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; NANOPARTICLE; PARASITE ANTIGEN; PROTOZOAL VACCINE; RECOMBINANT VACCINE; TOXOPLASMA GONDII VACCINE; UNCLASSIFIED DRUG;

ANIMAL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; CHEMISTRY; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG SYNTHESIS; ENZYME DEGRADATION; FEMALE; IMMUNE RESPONSE; IMMUNOLOGY; IN VIVO STUDY; METHODOLOGY; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; SYNTHESIS; TOXOPLASMA; TOXOPLASMA GONDII; TOXOPLASMOSIS; ZETA POTENTIAL;

EID: 0141888319     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5173(03)00377-6     Document Type: Article

References (28)

1. Artursson P., Lindmark T., Davis S.S., Illum L. Effect of chitosan on the permeability of monolayers of intestinal epithelial cells (Caco-2). Pharm. Res. 11:1994;1358-1361.
2. Bonenfant C., Dimier-Poisson I., Velge-Roussel F., Buzoni-Gatel D., Del Giudice G., Rappuoli R., Bout D. Intranasal immunization with SAG1 and nontoxic mutant heat-labile enterotoxins protects mice against Toxoplasma gondii. Infect. Immun. 69:2001;1605-1612.
3. Bourguin I., Chardes T., Bout D. Oral immunization with Toxoplasma gondii antigens in association with cholera toxin induces enhanced protective and cell-mediated immunity in C57BL/6 mice. Infect. Immun. 61:1993;2082-2088.
4. Debard N., Buzoni-Gatel D., Bout D. Intranasal immunization with SAG1 protein of Toxoplasma gondii in association with cholera toxin dramatically reduces development of cerebral cysts after oral infection. Infect. Immun. 64:1996;2158-2166.
5. Denkers E.Y. T lymphocyte-dependent effector mechanisms of immunity to Toxoplasma gondii. Microbes Infect. 1:1999;699-708.
6. Denkers E.Y., Gazzinelli R.T. Regulation and function of T-cell-mediated immunity during Toxoplasma gondii infection. Clin. Microbiol. Rev. 11:1998;569-588.
7. Dubey, J.P., Beattie, C.P., 1988. Toxoplasmosis of Animals and Man. CRC Press, Boca Raton.
8. Duquesne V., Auriault C., Gras-Masse H., Boutillon C., Darcy F., Cesbron-Delauw M.F., Tartar A., Capron A. Identification of T cell epitopes within a 23-kDa antigen (P24) of Toxoplasma gondii. Clin. Exp. Immunol. 84:1991;527-534.
9. Franken K.L., Hiemstra H.S., van Meijgaarden K.E., Subronto Y., den Hartigh J., Ottenhoff T.H., Drijfhout J.W. Purification of his-tagged proteins by immobilized chelate affinity chromatography: the benefits from the use of organic solvent. Protein Expr. Purif. 18:2000;95-99.
10. Holliman R.E. Congenital toxoplasmosis: prevention screening and treatment. J. Hosp. Infect. 30:1995;179-190.
11. Illum L., Jabbal-Gill I., Hinchcliffe M., Fisher A.N., Davis S.S. Chitosan as a novel nasal delivery system for vaccines. Adv. Drug Deliv. Rev. 51:2001;81-96.
12. Kumar M., Behera A.K., Lockey R.F., Zhang J., Bhullar G., De La Cruz C.P., Chen L.C., Leong K.W., Huang S.K., Mohapatra S.S. Intranasal gene transfer by chitosan-DNA nanospheres protects BALB/c mice against acute respiratory syncytial virus infection. Hum. Gene Ther. 13:2002;1415-1425.
13. Luessen H.L., de Leeuw B.J., Langemeyer M.W., de Boer A.B., Verhoef J.C., Junginger H.E. Mucoadhesive polymers in peroral peptide drug delivery. VI. Carbomer and chitosan improve the intestinal absorption of the peptide drug buserelin in vivo. Pharm. Res. 13:1996;1668-1672.
14. van der Lubben I.M., Konings F.A., Borchard G., Verhoef J.C., Junginger H.E. In vivo uptake of chitosan microparticles by murine Peyer's patches: visualization studies using confocal laser scanning microscopy and immunohistochemistry. J. Drug Target. 9:2001a;39-47.
15. van der Lubben I.M., Verhoef J.C., Borchard G., Junginger H.E. Chitosan for mucosal vaccination. Adv. Drug Deliv. Rev. 52:2001b;139-144.
16. van der Lubben I.M., Verhoef J.C., van Aelst A.C., Borchard G., Junginger H.E. Chitosan microparticles for oral vaccination: preparation, characterization and preliminary in vivo uptake studies in murine Peyer's patches. Biomaterials. 22:2001c;687-694.
17. Mao H.Q., Roy K., Troung-Le V.L., Janes K.A., Lin K.Y., Wang Y., August J.T., Leong K.W. Chitosan-DNA nanoparticles as gene carriers: synthesis, characterization and transfection efficiency. J. Control. Release. 70:2001;399-421.
18. McNeela E.A., O'Connor D., Jabbal-Gill I., Illum L., Davis S.S., Pizza M., Peppoloni S., Rappuoli R., Mills K.H. A mucosal vaccine against diphtheria: formulation of cross reacting material (CRM(197)) of diphtheria toxin with chitosan enhances local and systemic antibody and Th2 responses following nasal delivery. Vaccine. 19:2000;1188-1198.
19. O'Hagan D.T. Microparticles and polymers for the mucosal delivery of vaccines. Adv. Drug Deliv. Rev. 34:1998;305-320.
20. Raghuvanshi R.S., Katare Y.K., Lalwani K., Ali M.M., Singh O., Panda A.K. Improved immune response from biodegradable polymer particles entrapping tetanus toxoid by use of different immunization protocol and adjuvants. Int. J. Pharm. 245:2002;109-121.
21. Roy K., Mao H.Q., Huang S.K., Leong K.W. Oral gene delivery with chitosan-DNA nanoparticles generates immunologic protection in a murine model of peanut allergy. Nat. Med. 5:1999;387-391.
22. + T cells to control acute Toxoplasma gondii infection. Infect. Immun. 71:2003;309-316.
23. Supply P., Sutton P., Coughlan S.N., Bilo K., Saman E., Trees A.J., Cesbron Delauw M.F., Locht C. Immunogenicity of recombinant BCG producing the GRA1 antigen from Toxoplasma gondii. Vaccine. 17:1999;705-714.
24. Velge-Roussel F., Marcelo P., Lepage A.C., Buzoni-Gatel D., Bout D.T. Intranasal immunization with Toxoplasma gondii SAG1 induces protective cells into both NALT and GALT compartments. Infect. Immun. 68:2000;969-972.
25. van der Lubben I.M., Kersten G., Fretz M.M., Beuvery C., Coos Verhoef J., Junginger H.E. Chitosan microparticles for mucosal vaccination against diphtheria: oral and nasal efficacy studies in mice. Vaccine. 21:2003;1400-1408.
26. Vercammen M., Scorza T., Huygen K., De Braekeleer J., Diet R., Jacobs D., Saman E., Verschueren H. DNA vaccination with genes encoding Toxoplasma gondii antigens GRA1, GRA7, and ROP2 induces partially protective immunity against lethal challenge in mice. Infect. Immun. 68:2000;38-45.
27. Wikingsson L., Sjoholm I. Polyacryl starch microparticles as adjuvant in oral immunisation, inducing mucosal and systemic immune responses in mice. Vaccine. 20:2002;3355-3363.
28. Yap G.S., Sher A. Cell-mediated immunity to Toxoplasma gondii: initiation, regulation and effector function. Immunobiology. 201:1999;240-247.